The FDA has issued a warning that GLP-1 obesity drugs like Ozempic, Wegovy, Zepbound, and Mounjaro may carry an increased risk of NAION, a rare eye condition causing permanent vision loss due to restricted blood flow to the optic nerve. Drug manufacturers will now be required to add warnings about this risk to their labels, though the exact mechanism and strength of the link remain uncertain given confounding risk factors like diabetes and cardiovascular disease.
Background
GLP-1 receptor agonists have become among the most widely prescribed weight-loss and diabetes medications globally, with sales exceeding tens of billions annually. The FDA's safety communication adds a new label warning to an already heavily scrutinized class of drugs.
- Source
- Ars Technica
- Published
- Nov 10, 2026 at 10:43 PM
- Score
- 7.0 / 10